This site has referenced peptides repeatedly — MOTS-c, tesamorelin, and the broader idea of peptide therapy as an adjunct within comprehensive care. I've always tried to frame those references conservatively, and I want to now back up and build the foundation those references were resting on: what a peptide actually is, how it works mechanistically, and — because this genuinely matters — how the regulatory landscape around peptides actually functions right now.
What a peptide actually is
A peptide is a short chain of amino acids linked together — smaller than a full protein, but built from the same basic building blocks. Your body makes and uses peptides constantly as part of normal physiology: insulin is a peptide. So are several of the appetite-regulating hormones I've written about throughout this site, including the GLP-1 pathway itself. When a peptide is used therapeutically, it's typically either a naturally occurring peptide given in higher or more sustained amounts than the body produces on its own, or a modified version engineered for a longer half-life, better receptor targeting, or improved stability.
Mechanistically, peptides generally work by binding to specific receptors on cell surfaces, triggering a signaling cascade inside the cell — similar in principle to how a key fits a specific lock. This is part of why peptides tend to be quite selective in what they do, compared to some small-molecule drugs that interact more broadly across multiple systems.
Why administration route matters
Most therapeutic peptides are injected rather than taken as a pill, and this isn't a marketing or convenience decision — it's a real biochemical constraint. Peptides are proteins, structurally, and your digestive system is specifically built to break proteins down into individual amino acids before absorbing them. A peptide taken orally largely gets digested before it can act as the intact peptide it needs to be. Some newer formulations have found ways around this for select peptides, but injectable administration remains the default for a structural reason, not an arbitrary one.
The regulatory landscape, and why it's more complicated than "approved or not"
This is the part I think deserves the most attention, because the language used online — "FDA-approved" versus "research chemical" — makes it sound like a simple binary. It isn't. There are actually several distinct categories, and understanding them matters for evaluating any specific peptide you might come across.
FDA-approved prescription drugs. These have gone through the full clinical trial and approval process — the same process I've described at length in the posts on STEP and SURMOUNT trial data. Semaglutide, tirzepatide, and tesamorelin, all covered elsewhere on this site, fall into this category. Insulin does too. This is the strongest evidence tier, and it's the standard I hold every other claim on this site to.
Compounded peptides. Separate from full drug approval, certain peptides can legally be prepared by licensed compounding pharmacies under specific FDA frameworks, provided the substance is on an approved list and the patient has a valid prescription. This is a real, regulated pathway — but it is not the same as full FDA drug approval, and it's worth understanding that distinction clearly rather than assuming compounded automatically means equivalent to approved.
Research chemicals. Many of the peptides most discussed in wellness and biohacking spaces — including several I've referenced on this site with appropriately cautious framing — are currently sold as "research use only," explicitly not intended for human consumption. This exists in a genuine legal gray area: purchasing for legitimate laboratory research is legal, but self-administration isn't FDA-sanctioned, and the manufacturing and testing standards for these products vary enormously with essentially no guaranteed oversight. This isn't a theoretical concern — I've written separately about a real, ongoing cluster of hospitalizations tied to exactly this kind of unregulated sourcing, and it's worth reading before considering any peptide obtained outside a legitimate medical channel.
A live example of how this actually plays out
This isn't abstract. In late July 2026, the FDA's Pharmacy Compounding Advisory Committee met specifically to evaluate several peptides — including MOTS-c, which I've discussed on this site — for potential inclusion on the compounding pathway list. The committee reviewed seven peptides and voted to recommend six of them for that pathway, against the recommendation of the FDA's own staff, who had advised against all seven.
I want to walk through why this result is more nuanced than headlines about it suggest. A favorable committee vote is a recommendation regarding compounding access — it is not FDA drug approval, and it doesn't mean the peptide has been established as safe and effective in the way semaglutide or tesamorelin have. Formal rulemaking still has to follow, a process expected to extend into 2027. This is precisely the kind of distinction I think patients deserve to have explained clearly rather than glossed over: "recommended for a compounding pathway" and "FDA-approved therapeutic" are different claims, even when the same peptide name shows up in coverage of both.
Why this framework matters going forward
I'm laying this out now because I think every peptide-specific post that follows in this series will make more sense against this backdrop. When a peptide is discussed here, I'll try to be explicit about which of these categories it currently falls into — FDA-approved, on a real compounding pathway, or still squarely in research-chemical territory — because that distinction changes what can honestly be said about it, and it's the same evidence-tier discipline I've applied to every other claim across this site.
In the next post, I'll lay out the actual framework I use for evaluating any individual peptide, before applying it to specific compounds in the posts that follow.
Curious how a specific peptide you've heard about fits into this framework?
No spam. Occasional new posts and updates from The Center for Metabolic Health.
Medical disclaimer: This content is provided for general educational and informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any condition, and it does not create a physician-patient relationship. Every patient's medical history, health status, and treatment needs are different. Always consult your own physician or qualified healthcare provider before starting, stopping, or changing any medication or treatment, and before making any decisions based on information found here. If you are experiencing a medical emergency, call 911 or go to your nearest emergency room.